Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

Abstract

Pembrolizumab 2mg/kg q3w is a safe option in UM patients. Disease control rates, particularly in the subgroup of patients without progressive liver disease at the outset are promising; these results merit further investigation in clinical trials possibly incorporating liver targeted treatment modalities.